-
Mashup Score: 20
Heart failure (HF) remains a major cause of morbidity and mortality worldwide. Major advancements in optimal guideline-directed medical therapy, including novel pharmacological agents, are now available for the treatment of chronic HF including HF with reduced ejection fraction and HF with preserved ejection fraction. Despite these efforts, there are several limitations of medical therapy including but not limited to: delays in implementation and/or initiation; inability to achieve target dosing; tolerability; adherence; and recurrent and chronic costs of care.
Source: www.jscai.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 3ESC 2023 – Heart Failure Guideline Review - 4 month(s) ago
In this short video series, recorded at ESC 2023 in Amsterdam, Prof Carolyn Lam (National Heart Centre Singapore, SG) and Prof Giuseppe Rosano (St George’s University Medical
Source: www.radcliffecardiology.comCategories: General Medicine News, Cardiologists1Tweet-
@lamcardio and @GMCRosano discuss early detection in improving outcomes and highlight the significance of accessible and efficient diagnostic testing to prevent #HF in high-risk patients. ➡️ https://t.co/7s9d7g3u0j Supported by an unrestricted educational grant from AstraZeneca. https://t.co/ij1Y0SI8zG
-
-
Mashup Score: 1Sex differences in long‐term outcomes following acute heart failure hospitalization: Findings from the Get With The Guidelines‐Heart Failure registry - 5 month(s) ago
(A) Females with heart failure (HF) have excess life years lost after index HF hospitalization than males when compared with the median sex- and age-specific US life expectancy and (B) females have h…
Source: onlinelibrary.wiley.comCategories: Cardiologists, Latest HeadlinesTweet-
In this #GWTG cohort of 156K pts hospitalized for #HF 👵🏼 (vs 👨🏼🦳) had ⬇️adj mortality (esp in #HFrEF) ⬆️ readmission (esp in #HFpEF) ⬆️loss in survival time compared to median age- and sex-matched US population at 5 y Led by @ambarish4786 @NeilKeshvani https://t.co/6WMKNGqOti https://t.co/6AItnXjVYB
-
-
Mashup Score: 1
AbstractAims. Subcutaneous (SC) furosemide has potential advantages over intravenous (IV) furosemide by enabling self-administration or administration by a lay
Source: academic.oup.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 9Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients - 6 month(s) ago
Both selective and nonselective beta-blockers are used to treat patients with heart failure (HF). However, the data on the association of beta-blocker…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 13Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials - 6 month(s) ago
AbstractAims. Adjustment of treatment based on remote monitoring of pulmonary artery (PA) pressure may reduce the risk of hospital admission for heart failure (
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
The role of remote monitoring of pulmonary artery pressure in reducing hospital admission for heart failure. Read the meta-analysis of three randomized controlled trials in #EHJ. https://t.co/ckqHfYTUa5 #HF #pulmonarypressure #monitoring #cardiotwitter @ESC_Journals @escardio https://t.co/sIWKfIPQE0
-
-
Mashup Score: 18Differences between heart failure specialists and non‐specialists regarding heart failure drug implementation and up‐titration - 6 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: Cardiologists1, Latest HeadlinesTweet
-
Mashup Score: 15Differences between heart failure specialists and non‐specialists regarding heart failure drug implementation and up‐titration - 6 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3Home - 6 month(s) ago
Heart failure (HF) is a major cause of morbidity and mortality in the United States, with a prevalence that is expected to increase from about 6 million today to more than 8 million by 2030. A growing body of evidence pinpoints iron deficiency (ID) as an important comorbidity of HF, affecting more than 50% of patients with stable HF. Although the correction of ID is critical to improve outcomes in patients with HF, clinicians often overlook ID when providing HF care. Join our panel of experts for an
Source: na.eventscloud.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Registration | HFSA - 6 month(s) ago
The HFSA Annual Scientific Meeting 2023 offers a registration option that meets everyone’s needs. Whether you’ re just getting started in your career, or are a long-time veteran in the heart failure field, we’ ve taken each member of the care team into account. HFSA is pleased to offer a 10% discount for groups of 10 or more individual registrations to attend the Annual Scientific Meeting. See below for more information! HFSA membership is now complimentary for trainees. Become a member to get the
Source: hfsa.orgCategories: Latest Headlines, Partners & KOLsTweet
RT @SarasVallabhMD: Read our invited review on med/device mgmt of #HF published in @MyJSCAI - https://t.co/9PRzTVa1TW. Congratulations to @…